Dosage Forms

Articles

Adopting a seven-step process to maintenance and storage improves tableting quality.

Solving Tableting and Tooling Problems

Adopting a seven-step process resolves tableting problems.

Improving Tablet-Press Tooling Maintenance and Storage

Dr. Charles Kettler, director of Natoli Scientific, looks at the challenges that tablet scoring poses to tablet manufacturers.

The Challenge for Manufacturers in Tablet Splitting

Tim Freeman of Freeman Technology explains how new analytical technologies have influenced quality criteria and standards for the uniformity of dosage units, and why more accurate systems are leading to greater focus on tablet scoring.

Tablet Splitting and Analytical Technologies

When splitting unscored tablets, the main concerns relate to API dosage control and the potential modification of time-release characteristics. PTE speaks with tableting experts Thierry Menard, Lab Manager, And Bruno Villa, President, both at Medelpharm, about how manufacturers are approaching the challenges.

Tablet Splitting Concerns

Tablet splitting is a new area of focus for regulators. The FDA tells PTE more about the challenges in this area.

Tablet Splitting: A New Focus for Regulators

GlaxoSmithKline recently developed a novel technology for the formulation of modified-release tablets. The authors describe the route from development to commercialization.

Development and Commercialization of a Novel Modified Release Tablet Technology

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Particle-engineering technologies, such as crystal design for crystallization and producting cocrystals, particle-size reduction, and amorphous solid dispersions, help to optimize delivery of a drug.

Seeking Solutions in Solid-State Chemistry

Fluid-Bag Ltd provides comprehensive 900 and 1000 litre flexible IBC systems for liquid and semi-solid products, including filling and discharging equipment. The GMP compliant container system is designed to guarantee uniform liquid, maximise payload and minimise discharge residue (0.5% residue).

Solid/Semi-Solid Dosage